HOZOT是最近发现的新型调节性T细胞亚群，该群细胞除了可以抑制效应T细胞的活化，还具有强大的细胞毒作用，具有良好的临床应用前景。前期的研究结果显示，抗CD40L抗体可以促进胃癌恶性腹水中分选的CD4+CD25+CD127-调节性T细胞并上调Foxp3的表达。同时还发现腹水中存在HOZOT相同特征的细胞浸润。结合相关研究，我们提出科研假说：阻断CD40/CD40L信号可以促进HOZOT的体外扩增，而扩增后的HOZOT可以用于胃癌的免疫过继治疗。为了验证这一假说，我们以胃癌微环境中浸润和体外诱导的HOZOT为切入点，通过相关免疫学技术，系统分析CD40/CD40L信号在HOZOT增殖中的作用。为进一步建立基于CD40/CD40L信号通路及HOZOT细胞为基础的胃癌免疫治疗新策略提供理论依据和实验数据。

HOZOT is a group of novel regulatory T cells discovered recently, in addition to inhibit T cell activation , but also has a strong cytotoxicity and proliferation, which could invade into the tumor cells through phagocytosis way , and have good prospects for clinical application in the future. Previous studies showed that anti-CD40L antibody can promote CD4+CD25+CD127-regulatory T cells proliferation and Foxp3 upregulated expression which sorting from malignant ascites of gastric. We also found the cells same characteristic as HOZOT infiltration in ascites. Combined with previous studies, we propose research hypotheses: Blocking CD40/CD40L signal can promote HOZOT amplification in vitro, and amplified HOZOT can be used in gastric adoptive immune therapy . To test and verify this hypothesis, we analysis the role of CD40/CD40L signal in HOZOT proliferation through immunological techniques base on infiltrated in gastric cancer microenvironment and induced HOZOT in vitro. We hope to provide experimental data and basis theoretical in immunotherapy based on HOZOT and CD40/CD40L signaling pathway in the further.